22:56 , Apr 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies identified p53-activating tetrahydroindazole-based DHODH inhibitors that could help treat melanoma. Screening of a small molecule library in human melanoma cell line-based assays of p53-dependent transcription, followed by chemical synthesis...
22:30 , Apr 14, 2017 |  BioCentury  |  Emerging Company Profile

Tolerating DHODH

Immunic AG is betting on the tolerability and efficacy of its oral, next-generation dihydroorotate dehydrogenase inhibitor to differentiate it from first-generation agents and give it an edge over other types of oral therapies in the...
01:03 , Feb 16, 2017 |  BC Innovations  |  Emerging Company Profile

Autoimmunity alternative

Inhibiting the nucleotide biosynthetic pathway in autoimmune diseases is one way to avoid the risks of broad immunosuppression, but the marketed compounds have serious side effects of their own. Step Pharma is pursuing a safer...
07:00 , Oct 20, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML) Mouse studies suggest inhibiting DHODH could help treat acute AML. In two mouse models of AML, a DHODH inhibitor tool compound increased survival and the levels of markers of differentiation and...
07:00 , May 9, 2016 |  BC Week In Review  |  Clinical News

PRTX-100: Preliminary Phase I/II data

Preliminary data from 8 patients with active RA in the per protocol (PP) population of part 1 of the 2-part, open-label, U.S. Phase I/II SPARTA-II (PRTX-100-105) trial showed that IV PRTX-100 for 6 months reduced...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Company News

Sanofi sales and marketing update

Sanofi launched in the U.S. an authorized generic version of its Arava leflunomide to treat rheumatoid arthritis (RA). The pyrimidine synthesis inhibitor has a wholesale acquisition cost (WAC) of $5 per 10 mg tablet....
08:00 , Nov 24, 2014 |  BC Week In Review  |  Clinical News

PRTX-100: Additional Phase Ib data

Additional data from 61 patients with active RA in the first 5 cohorts of the double-blind, placebo-controlled, U.S. Phase Ib SPARTA (PRTX-100-104) trial showed that IV PRTX-100 plus methotrexate or leflunomide was well tolerated...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Clinical News

PRTX-100: Interim Phase Ib data

Interim data from 41 patients with active RA in the first 4 cohorts of the double-blind, placebo-controlled, U.S. Phase Ib SPARTA (PRTX-100-104) trial showed that once-weekly 1.5, 3, 6 and 12 ug/kg doses of IV...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Clinical News

Aubagio teriflunomide regulatory update

The European Commission approved an MAA from Sanofi for Aubagio teriflunomide to treat relapsing-remitting multiple sclerosis (RRMS). Sanofi said it plans to launch Aubagio in Europe "in the coming months," with the first launch slated...
23:58 , Aug 30, 2013 |  BC Extra  |  Company News

Aubagio gets European approval for MS

The European Commission approved an MAA from Sanofi (Euronext:SAN; NYSE:SNY) for Aubagio teriflunomide to treat relapsing-remitting multiple sclerosis (RRMS). Sanofi said it plans to launch Aubagio in Europe "in the coming months," with the first...